Katherine Beebe - Jul 26, 2023 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Role: President and COO, Director
Signature: /s/ Katherine Beebe DeVarney
Stock symbol: TTNP
Transactions as of: Jul 26, 2023
Transactions value $: $0
Form type: 4
Date filed: 7/28/2023, 05:45 PM
Previous filing: Jan 5, 2022
Next filing: Oct 26, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TTNP	Common Stock	Award	$0	+50K		$0.00	50K	Jul 26, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TTNP	Option to Purchase Common Stock	Award	$0	+100K		$0.00	100K	Jun 29, 2023	Common Stock	100K	$1.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
F2	The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

Content

The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.